Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3384-3397

  Huang, Jenny Li Ying ^a   Urtatiz, Oscar ^a   Van Raamsdonk, Catherine D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; PROTEIN GNAQ Q209L; UNCLASSIFIED DRUG; YAP PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

ADULT; ADULTHOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLUE NEVUS; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INNER EAR; LUNG METASTASIS; MELANOCYTE; MELANOCYTOSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ROSA26 GENE; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; TRANSGENIC MOUSE; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME; UVEA MELANOMA; 129 MOUSE; ANIMAL; BLOOD VESSEL; C3H MOUSE; C57BL MOUSE; CELL CULTURE; GENETICS; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; LUNG; MELANOMA; METABOLISM; MISSENSE MUTATION; PATHOLOGY; UVEA TUMOR; WESTERN BLOTTING;

ANIMALS; BLOOD VESSELS; BLOTTING, WESTERN; CELLS, CULTURED; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; LUNG; MELANOCYTES; MELANOMA; MICE, 129 STRAIN; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; SKIN PIGMENTATION; UVEAL NEOPLASMS;

EID: 84943182095     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3229     Document Type: Article

References (56)

1. Singh AD, Turell ME, Topham AK Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-5.
2. Van Raamsdonk C.D., Griewank KG, Crosby M.B., Garrido MC, Vemula S, Wiesner T, et al Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-9.
3. Van Raamsdonk C.D., Bezrookove V, Green G., Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
4. Abdel-Rahman M.H., Pilarski R, Cebulla C.M., Massengill JB, Christopher BN, Boru G, et al Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011; 48: 856-9.
5. Furney SJ, Pedersen M, Gentien D., Dumont AG, Rapinat A, Desjardins L, et al SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013; 3: 1122-9.
6. Harbour JW, Onken MD, Roberson E.D., Duan S., Cao L, Worley LA, et al Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-3.
7. Martin M, Masshofer L, Temming P., Rahmann S, Metz C, Bornfeld N., et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933-6.
8. Dono M, Angelini G, Cecconi M., Amaro A, Esposito AI, Mirisola V, et al Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer 2014; 110: 1058-65.
9. Hubbard KB, Hepler JR Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal 2006; 18: 135-50.
10. Offermanns S, Zhao LP, Gohla A, Sarosi I., Simon MI, Wilkie TM. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q/G alpha 11-mutant mice. EMBO J 1998; 17: 4304-12.
11. Chen X, Wu Q, Tan L., Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2013; 33: 4724-34.
12. Yu FX, Luo J, Mo J.S., Liu G., Kim YC, Meng Z, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014; 25: 822-30.
13. Feng X, Degese MS, Iglesias-Bartolome R, Vaque J.P., Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014; 25: 831-45.
14. Markby DW, Onrust R, Bourne HR Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 1993; 262: 1895-901.
15. Sondek J, Lambright DG, Noel J.P., Hamm HE, Sigler PB. GTPase mechanism of Gproteins from the 1.7-A crystal structure of transducin alpha-GDP-AIF-4. Nature 1994; 372: 276-9.
16. Landis CA, Masters SB, Spada A, Pace A.M., Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692-6.
17. Weinstein LS, Shenker A, Gejman P.V., Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-95.
18. Kusters-Vandevelde H.V., Klaasen A, Kusters B., Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010; 119: 317-23.
19. Kusters-Vandevelde H.V., van Engen-van Grunsven IA, Kusters B, van Dijk MR, Groenen PJ, Wesseling P, et al. Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol 2010; 120: 755-64.
20. Murali R, Wiesner T, Rosenblum M.K., Bastian BC. GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuro-pathol 2012; 123: 457-9.
21. Gessi M, Hammes J, Lauriola L., Dorner E, Kirfel J, Kristiansen G., et al. GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 2013; 39: 417-25.
22. Forbes SA, Bindal N, Bamford S., Cole C, Kok CY, Beare D, et al COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue):D945-50.
23. Turajlic S, Furney SJ, Stamp G, Rana S., Ricken G, Oduko Y, et al Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol 2014; 25: 959-67.
24. Beadling C, Heinrich MC, Warrick A, Forbes E.M., Nelson D., Justusson E, et al. Multiplex mutation screening bymass spectrometry evaluation of820 cases from a personalized cancer medicine registry. J Mol Diagn 2014; 13:504-13.
25. Wilson MA, Zhao F, Letrero R., D'Andrea K, Rimm DL, Kirkwood J.M., et al. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 2014; 20: 3328-37.
26. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239-71.
27. Lamba S, Felicioni L, Buttitta F., Bleeker FE, Malatesta S, Corbo V, et al Mutational profile of GNAQQ209 in human tumors. PLoS ONE 2009; 4: e6833.
28. Dratviman-Storobinsky O., Cohen Y, Frenkel S., Pe'er J, Goldenberg-Cohen N. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. Invest Ophthalmol Vis Sci 2010; 51: 6180-2.
29. Kim CY, Kim DW, Kim K, Curry J., Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer 2014; 14: 516.
30. Takemoto Y, Keighren M, Jackson I.J., Yamamoto H. Genomic localization of a Dct-LacZ transgene locus: a simple assay for transgene status. Pigment Cell Res 2006; 19: 644-5.
31. Alizadeh A, Fitch KR, Niswender C.M., McKnight GS, Barsh GS. Melanocyte-lineage expression of Cre recombinase using Mitf regulatory elements. Pigment Cell Melanoma Res 2008; 21: 63-9.
32. Bosenberg M, Muthusamy V, Curley D.P., Wang Z., Hobbs C, Nelson B, et al Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006; 44: 262-7.
33. Sviderskaya EV, Bennett DC, Ho L, Bailin T., Lee ST, Spritz RA. Complementation of hypopigmentation in p-mutant (pink-eyed dilution) mouse melanocytes by normal human P cDNA, and defective complementation by OCA2 mutant sequences. J Invest Dermatol 1997; 108: 30-4.
34. Royo JL, Hidalgo M, Ruiz A. Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc 2007; 2: 1734-9.
35. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70-1.
36. Deo M, Huang JL, Fuchs H, de Angelis MH, Van Raamsdonk CD. Differential effects of neurofibromin gene dosage on melanocyte development. J Invest Dermatol 2013; 133: 49-58.
37. Pollock PM, Cohen-Solal K, Sood R., Namkoong J, Martino JJ, Koganti A, et al Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003; 34: 108-12.
38. Mackenzie MA, Jordan SA, Budd P.S., Jackson IJ. Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. Dev Biol 1997; 192: 99-107.
39. Heegaard S, Jensen OA, Prause JU Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res 2000; 10: 350-4.
40. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 1993; 100: 208-15.
41. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15: 294-303.
42. Anderson MG, Libby RT, Mao M, Cosma I.M., Wilson LA, Smith RS, et al. Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC Biol 2006; 4: 20.
43. Kim H, Ankamreddy H, Lee D.J., Kong KA, Ko HW, Kim MH, et al Pax3 function is required specifically for inner ear structures with melanogenic fates. Biochem Biophys Res Commun 2014; 445: 608-14.
44. Wakaoka T, Motohashi T, Hayashi H., Kuze B, Aoki M, Mizuta K., et al. Tracing Sox10-expressing cells elucidates the dynamic development of the mouse inner ear. Hear Res 2013; 302: 17-25.
45. Hozumi H, Takeda K, Yoshida-Amano Y, Takemoto Y., Kusumi R, Fukuzaki-Dohi U, et al. Impaired development of melanoblasts in the black-eyed white Mitf(mi-bw) mouse, a model for auditory-pigmentary disorders. Genes Cells 2012; 17: 494-508.
46. Cable J, Huszar D, Jaenisch R., Steel KP. Effects of mutations at the W locus (c-kit) on inner ear pigmentation and function in the mouse. PigmentCell Res 1994; 7: 17-32.
47. Navarrete CM, Ruah CB, Schachern P, Paparella MM Normal and meta-static melanin in the temporal bone. Am J Otolaryngol 1995; 16: 33-9.
48. Fitch KR, McGowan KA, van Raamsdonk CD, Fuchs H, Lee D, Puech A, et al. Genetics of dark skin in mice. Genes Dev 2003; 17: 214-28.
49. Van Raamsdonk C.D., Fitch KR, Fuchs H, de Angelis MH, Barsh GS. Effects of G-protein mutations on skin color. Nat Genet 2004; 36: 961-8.
50. Deo M, Huang JL, Van Raamsdonk CD. Genetic interactions between neurofibromin and endothelin receptor B in mice. PLoS One 2013; 8: e59931.
51. Takayama H, La Rochelle WJ, Anver M, Bockman DE, Merlino G. Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci U S A 1996; 93: 5866-71.
52. Benaduce AP, Batista D, Grilo G., Jorge K, Cardero D, Milikowski C., et al. Novel UV-induced melanoma mouse model dependent on Endothelin3 signaling. Pigment Cell Melanoma Res 2014; 27: 839-42.
53. Saldanha G, Purnell D, Fletcher A., Potter L, Gillies A, Pringle JH High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004; 111: 705-10.
54. Levy C, Khaled M, Fisher DE MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12: 406-14.
55. Beermann F, Schmid E, Schutz G. Expression of the mouse tyrosinase gene during embryonic development: recapitulation of the temporal regulation in transgenic mice. Proc Natl Acad Sci U S A 1992; 89: 2809-13.
56. Garraway LA, Widlund HR, Rubin M.A., Getz G., Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436: 117-22.